Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926004 | 0.81 | DDB1 (0.43) | HDAC9TACR1TACR3NPC1RAB9A | |
| SCHEMBL3930950 | 0.76 | KDM1A (0.38) | HDAC9TACR1TACR3HCAR2 | |
| SCHEMBL8522929 | 0.73 | KDM4E (0.42) | HDAC9AKR1B1SIGMAR1ALDH1A1TP53 | |
| SCHEMBL18088631 | 0.68 | CTSL (0.44) | ALDH1A1TP53TSHRNPC1RAB9A | |
| SCHEMBL23223713 | 0.66 | HDAC9 (0.38) | HDAC9SIGMAR1ALDH1A1TP53CYP1A2 | |
| SCHEMBL9430169 | 0.66 | TSHR (0.43) | ALDH1A1TP53TSHRNPC1RAB9A | |
| SCHEMBL9431035 | 0.66 | TSHR (0.43) | ALDH1A1TP53TSHRNPC1RAB9A | |
| SCHEMBL9430176 | 0.66 | TSHR (0.43) | ALDH1A1TP53TSHRNPC1RAB9A | |
| SCHEMBL7450984 | 0.65 | HDAC9 (0.44) | HDAC9SIGMAR1TSHRTACR1TACR3 | |
| SCHEMBL1153942 | 0.64 | TACR3 (0.53) | HDAC9SIGMAR1ALDH1A1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541579-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130131338-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-8367673-B2 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | GLAXO GROUP LIMITED | 2009-07-23 | — | — | US | disclosed |
| US-7514437-B2 | Substituted diketopiperazines as oxytocin antagonists | SMITHKLINE BEECHAM CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | disclosed |
| EP-1458393-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053443-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131338-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR2, CRH | HDAC9 2100/4885AKR1B1 1441/4885SIGMAR1 1197/4885 |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | HDAC9 3020/4885AKR1B1 1044/4885SIGMAR1 722/4885 |
| US-20090186867-A1 | Substituted Diketopiperazines As Oxytocin Antagonists | OXTR, AVPR2, CRH | HDAC9 2048/4885AKR1B1 1518/4885SIGMAR1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.